Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery and engineering of AiEvo2, a novel Cas12a nuclease for human gene editing applications.

The Journal of biological chemistry - 1 Mar 2024

Sharrar Allison, Arake de Tacca Luisa, Meacham Zuriah, Staples-Ager Johanna, Collingwood Trevor, Rabuka David, Schelle Michael

Abstract excerpt

The precision of gene editing technology is critical to creating safe and effective therapies for treating human disease. While the programmability of CRISPR-Cas systems has allowed for rapid innovation of new gene editing techniques, the off-target activity of these enzymes has hampered clinical development for novel therapeutics. Here, we report the identification and characterization of a novel CRISPR-Cas12a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR-Cas Systems
Share to Endonucleases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Editing

Share to HEK293 Cells

Share to Nanoparticles

Share to Nucleotides

Share to Proprotein Convertase 9

Share to Receptors, Chimeric Antigen

Source

Open in PubMed Open full text

Identifiers

PMID: 38272227
DOI: 10.1016/j.jbc.2024.105685
PMCID: PMC10877636

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery and engineering of AiEvo2, a novel Cas12a nuclease for human gene editing applications.PMID 38272227Read ↗

Discovery and engineering of AiEvo2, a novel Cas12a nuclease for human gene editing applicationsSemantic proximity Read ↗

Viral delivery of compact CRISPR-Cas12f for <i>in vivo</i> gene editing applicationsSemantic proximity Read ↗

AsCas12a ultra nuclease facilitates the rapid generation of therapeutic cell medicinesSemantic proximity Read ↗

Precision in Action: The Role of Clustered Regularly Interspaced Short Palindromic Repeats/Cas in Gene TherapiesSemantic proximity Read ↗

Improving FnCas12a genome editing by exonuclease fusionSemantic proximity Read ↗

Cas12a Ultra enables efficient genome editing in human multipotent and pluripotent stem cellsSemantic proximity Read ↗

Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular CarcinomaSemantic proximity Read ↗

Single-AAV CRISPR editing of skeletal muscle in non-human primates with NanoCas, an ultracompact nucleaseSemantic proximity Read ↗

CRISPR-Cas12a delivery by DNA-mediated bioresponsive editing for cholesterol regulationSemantic proximity Read ↗

All-in-One Adeno-associated Virus Delivery and Genome Editing by <i>Neisseria meningitidis</i> Cas9 <i>in vivo</i>Semantic proximity Read ↗

Allele-specific genome targeting in the development of precision medicine.Semantic proximity Read ↗

Human genetic variation alters CRISPR-Cas9 on- and off-targeting specificity at therapeutically implicated loci.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.